Articles
In defence of South Africa’s National Health Research Ethics Council guidelines on heritable human genome editing
Heart Failure Breakthrough? FINEARTS-HF Study Explores How Finerenone Impacts Different Ejection Fractions!
The effects of treatments for heart failure (HF) may vary among patients according to left ventricular ejection fraction (LVEF). In FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure), the nonsteroidal mineralocorticoid receptor antagonist finerenone reduced the risk of cardiovascular death and total worsening HF events in patients with HF with mildly reduced or preserved ejection fraction. We examined the effect of finerenone according to LVEF in FINEARTS-HF.
Click here to access the article.